Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513863 · ClinicalTrials.gov registry record · Phase 1
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
A Phase 1 study of Rosacea, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 602
- Enrollment target
- 20
- Study locations
NCT01513863 is a Phase 1 study of Rosacea that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 602 participants, above the 217-participant average among 23 other Rosacea trials with a reported enrollment target (177% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01513863, a Phase 1 study of Rosacea, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 602 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to demonstrate that metronidazole 1% topical gel is effective for the treatment of patients with moderate to severe rosacea.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metronidazole Topical Gel 1%
- DRUG Metronidazole Topical Gel 1% (Metrogel)
Study Locations (20)
Florida
- Investigator Site - Jacksonville
- Investigator Site - Miami
- Investigator Site - Miramar
North Carolina
- Investigator Site - Hickory
- Investigator Site - High Point
- Investigator Site - Wilmington
Tennessee
- Investigator Site - Kingsport
- Investigator Site - Knoxville
- Investigator Site - Nashville
California
- Investigator Site - Long Beach
- Investigator Site - Newport Beach
Arizona
- Investigator Site - Phoenix
Colorado
- Investigator Site - Denver
Illinois
- Investigator Site - Arlington Heights
Indiana
- Investigator Site - Plainfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513863
The ClinicalTrials.gov registry entry for NCT01513863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 23 other Rosacea trials with a reported enrollment target (177% higher). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01513863 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01513863 about?
NCT01513863 is a clinical study titled "A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea". The objective of this study is to demonstrate that metronidazole 1% topical gel is effective for the treatment of patients with moderate to severe rosacea.
What is the current status of trial NCT01513863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 602 participants. The study started on 2011-08. Estimated completion is 2012-09.
What conditions does trial NCT01513863 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01513863?
The interventions under investigation include: Placebo (DRUG), Metronidazole Topical Gel 1% (DRUG), Metronidazole Topical Gel 1% (Metrogel) (DRUG).
Who is sponsoring clinical trial NCT01513863?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01513863 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.